Connect with us

Cannabis News

Senator Blocks Confirmation Of Trump’s ‘Unqualified’ White House Drug Czar Pick Who Has Voiced Medical Marijuana Support

Published

on

A Democratic senator is holding back nearly 90 of President Donald Trump’s administration nominees, including the president’s pick for White House drug czar He says he is among many “unqualified” candidates who threaten to “undermine the rule of law and our national security.”

The Senate Judiciary Committee in October advanced the nomination of Sara Carter Bailey to join the administration as director of the Office of National Drug Control Policy (ONDCP). But when he was included in an en bloc confirmation package of 88 nominees, Sen. Michael Bennet (D-CO) raised a procedural question that led Republicans to stall the vote.

“I’ve just blocked 88 of Trump’s nominees for confirmation, including Sara Carter Bailey, the former Fox News contributor nominated to be our country’s drug czar,” Bennet said Thursday. “Bailey was nominated by Trump, who recently pardoned the former president of Honduras, who served 45 years in prison for conspiring to distribute more than 400 tons of cocaine.”

“I will not allow those without a candidate, this White House or the president to undermine the rule of law and our national security,” he said. he said.




The procedural complaint raised by Bennet relates to the ONDCP director being a “Tier I” executive officer.

Therefore, unlike the other candidates in the package, Bailey could not be included in the group vote – the body that was chaired by the Republican senator on Thursday. recognize.

Bailey, for his part, yes expressed his support for medical cannabis, while stating that he has “no problem” with legalizationeven if you may not personally agree with the policy.

A former journalist known for his coverage of drug cartels, Bailey also recently informed senators that the administration. keeping “all options” on the table as it continues to consider a proposal to reorganize marijuanawhile describing cannabis reform as a “bipartisan issue.”

Bennet isn’t the only senator questioning the nominee’s abilities. Before the committee’s vote in October, Sen. Dick Durbin (D-IL), the panel’s ranking member, called Bailey a Trump “loyalist” who was “appointed to a position that he is completely, utterly unqualified for.”

“He’s not a doctor or an addiction specialist,” she said. “He’s never been a prosecutor or a law enforcement officer.”

Given the ONDCP director’s role in setting and carrying out the administration’s agenda on drug policy issues, Bailey’s enthusiastic endorsement of medical cannabis in the past is welcome to advocates.

Senator Cory Booker (D-NJ) raised the issue of cannabis rescheduling one-on-one with the candidate in September, stating that the proposal to move marijuana from Schedule I to III of the Controlled Substances Act (CSA) would be a “step in the right direction.”

“It would open the door to more scientific research, so if you were to be confirmed, how would you advise the American president on the reprogramming process going on?” he asked.

Bailey said she shares Booker’s passion for the issue, which she described as “bipartisan.”

“If confirmed as director, I will comply with all federal laws and meet all legal responsibilities of ONDCP,” he said. “However, we will continue to work in depth with research and data. We will continue to do so and explore all options.”

Trump endorsed the redistricting on the campaign trail before his second term — as well as bank access to the marijuana industry and a ballot initiative to legalize Florida. But his latest comments in late August about the timing of the reorganization decision gave a more ambiguous impression of his stance on the matter.

While Bailey has spoken often on a variety of marijuana policy issues (focusing on illegal trafficking and illegal growing operations on US soil, for example), his public comments have been limited on how he personally feels about the issue. Last year, she said in an episode of her podcast, The Sara Carter Show, that she makes a distinction between legally regulated and illegally supplied marijuana.

“I don’t have a problem if it’s legalized and controlled,” he said. “I mean, maybe I have my own issues with how I feel about it, but I think it’s a wonderful way to handle cannabis for medicine and medical reasons — especially for people with cancer and other diseases, you know — to manage the disease and the side effects of those drugs and diseases. So I’m not saying we should make it illegal.”

If Bailey is ultimately confirmed by the Senate, he will be the second drug czar to come out in favor of medical marijuana. Former President Joe Biden’s ONDCP Director Rahul Guptaworked as a consultant to cannabis businesses and oversaw the implementation of West Virginia’s medical marijuana program.

On his social media, Bailey has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

the federal statute The drug czar is prohibited from agreeing to the legalization of Schedule I drugs in the CSA, including marijuana.

“The Director . . . shall ensure that federal funds appropriated to the Office of National Drug Control Policy shall not be expended for any study or contract related to the legalization (for medical use or any other use) of a substance listed in section I of section 812 of this title and shall take such measures as may be necessary to oppose any attempt to legalize the use (in any form) of a substance not listed in subparagraph (I)(B) of section 8 of section (I). The purpose of the Food and Drug Administration approved for medical use.

In April, on the other hand, the democratic members of Congress announced the introduction of a bill that would remove this restriction. It has yet to advance in the GOP-controlled Congress.

Bailey has separately sounded the alarm about the risk of pesticides and other contaminants in marijuana grown and sold by Chinese cartels…recently a House committee took up the matter.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Last year, the candidate discussed the issue with Derek Maltz, a now-retired Drug Enforcement Administration (DEA) official who is serving as the agency’s interim administrator before his confirmation. Trump’s perennial pick, Terrance Cole.

In an X post about the interview with Maltz, Bailey said how “Chinese marijuana growing operations are using dangerous chemicals as pesticides.”

In 2022, U.S. Representative Mike Garcia (R-CA) praised Bailey for working with his office to bring attention to illegal grow operations in his district, leading to an investigation by local law enforcement.

Bailey credited congress, saying, “The work you’ve done to get rid of illegal marijuana seeds has prevented the cartels from exploiting your community, the people forced to work in it, and (your money).”

In a 2021 interview with Fox News’ Sean Hannity, he also talked about his work with Garcia, including accompanying him on a helicopter, “a lot of sophisticated illegal farms worth billions of dollars.”

The posters “have become much bolder. They are not afraid to hide,” he said. “They don’t hide it because they don’t feel like they’ll ever be held accountable for it.”

In a sense, Bailey seems to be implicitly suggesting that he supports regulated access to cannabis as a means to promote public safety and health. Whether that implied position would influence federal policy and whether the role of ONDCP director is confirmed and assumed remains to be seen.

On his social media, he has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

Photo by Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

US Representatives introduce the Higher Education Marijuana Research Act

Published

on

By

Cannabis Caucus Co-Chairs Ilhan Omar (D-MN) and Dina Titus (D-NV) yesterday introduced the Higher Education Marijuana Research Act to remove barriers to academic cannabis research, protect universities and researchers, and promote the responsible study of marijuana.
“As Chair of the Congressional Cannabis Caucus, I am proud to support the Higher Education Marijuana Research Act, which removes outdated federal barriers that have long prevented universities from conducting critical cannabis research. This legislation protects universities and researchers while removing barriers so they can make better public health decisions,” said Congressman Ilhan Omar.
“The legal and responsible use of cannabis in Nevada has been an important economic driver across the country and deserves further investigation,” said Congressman Titus. “The Higher Education Marijuana Research Act would eliminate outdated federal restrictions that prevent universities and researchers from studying the full range of cannabis products that Americans actually use.”
Although 40 states have legalized medical marijuana and 24 states have legalized it for recreational use, federal law continues to impose significant barriers that limit meaningful research. Cannabis remains subject to restrictive federal controls that dictate who can conduct research, what products can be studied, and how studies are designed. Researchers are often limited to federally licensed cannabis that does not reflect the potency or variety available in state legal markets. Compounding these challenges, researchers must navigate stringent compliance requirements and uncertainty about legal liability. These obstacles have delayed clinical trials, limited understanding of long-term health effects, and left critical gaps in knowledge.

“It makes no sense for the federal government to interfere with this research when millions of Americans are already using marijuana, whether for medical or recreational purposes,” said Congressman Titus.

The Higher Education Marijuana Research Act is supported by the National Organization for Reform of Marijuana Laws (NORML), the National Cannabis Industry Association, the Drug Policy Alliance, and the UNLV Cannabis Policy Institute.

“This legislation is needed more than ever as states continue to allow cannabis for medical and adult use. Even if cannabis is federally reclassified in the near future, there will be significant hurdles for scientists hoping to add to the existing research pool, especially when conducting clinical trials on health effects and examining state-regulated products. The bill moves forward again and calls on Congress to take immediate action to facilitate research, develop new medical treatments, to inform evidence-based policy and help consumers make informed choices,” said Morgan Fox, Policy Director of the National Organization for Reform of Marijuana Laws (NORML).

“The American public has made it clear that it wants access to safe, regulated, and tested cannabis products, and state legal markets continue to evolve to meet that demand. However, federal barriers have long limited researchers’ ability to study hemp in ways that reflect real-world conditions. The Higher Education Marijuana Research Act is a practical step toward expanding credible, real-world research by providing clarity and protection for NCIA universities. Supporting this legislation will help strengthen the industry’s scientific foundation. and will help better inform policymakers, regulators and consumers,” said Brooke Gilbert, Chief Operating Officer of the National Cannabis Industry Association.

“The Higher Education Marijuana Research Act is common-sense legislation that will help researchers better understand the types of cannabis produced in state-regulated markets. The bill will remove a major barrier that currently prevents scientists from learning more about state-regulated cannabis and its public health implications. Increasing the body of scientific evidence with better-informed research, increasing the body of scientific evidence with more informed research, evidence-based policy anyone who should leave,” he said. Drug Markets and the Legal System.

“Everyone, from members of Congress on both sides of the aisle to the scientific community to the current and previous presidential administrations, has stated that cannabis research is necessary and important. This is the one issue that almost everyone can agree on these days, but not much progress is being made to reduce the current barriers to cannabis research. Congressman Titus’ bill has always been a common sense pro-cannabis research. Cannabis reform, it is only fitting that UNLV Cannabis Policy lead the charge now. The Institute applauds his efforts and hopes others will do the necessary work to reduce current barriers to cannabis research that only serve to maintain outdated prohibition-era policies,” said Riana Durrett, director of the UNLV Cannabis Policy Institute.

Source: Representative Ilhan Omar’s office

Continue Reading

Cannabis News

How Psychedelics Helped Me Manage Grief From A Career In Law Enforcement (Op-Ed)

Published

on

By

“What I experienced with ayahuasca was not an escape from grief, but a direct engagement with it… It was a fundamentally different process than what I had relied on throughout my career: not control or oppression, but forgiveness, surrender and understanding.”

By: Kemmi Sadler, Law Enforcement Action Partnership

Life has an interesting way of opening the eyes and the mind. Throughout my law enforcement career, I built my identity around evidence, discipline, and control. And to my surprise, it was this mindset that eventually led me to rethink everything I thought I knew about psychedelics.

My story begins with Amel. He was sixty years old and working for the US embassy in Iraq on his second tour when I arrived in 2006 as a bright-eyed young agent in the Diplomatic Security Service. In early 2007, her husband was kidnapped. He decided to save her, went to rescue her, and was taken away. Neither of them survived.

For the next 18 years, I felt I had to protect him—or at least stop him from going.

That guilt had a way of surfacing at unexpected moments. I felt how deeply grief had shaped me, even though I had kept it buried. But in a profession built around helping others, it’s hard to admit when you need help yourself.

So I went back to work.

My career included investigating fraud and human trafficking, followed by two years in internal affairs handling sexual assault and crimes against children. I prided myself on approaching each case without bias, following the evidence, testing hypotheses, and letting the facts guide me.

This commitment to evidence was ingrained early on, and it led me to question some basic assumptions about law enforcement. As a young police officer with the St. Augustine Police Department in Florida, I began to notice gaps between what the system was supposed to do and what it actually did. Not everyone was as afraid of arrest as I expected. Drug users, dealers, sex workers—they were often considered part of the equation. This time I got caught. Next time, I’ll be more careful.

Those early experiences brought to the fore a question I couldn’t shake: If consequences are supposed to change behavior, why not? I saw the same people over and over again through the system. A man, known to our department, got drunk, called 911 from a pay phone and yelled, “CHICKEN GEORGE IS COMING!” until the officers arrive. Looking back, I wonder if the detention itself offered something he didn’t get anywhere else—human interaction or just a night on the street.

The same instinct that led me to rethink aspects of my work also shaped how I began to deal with my unresolved grief. For years, I relied on the same framework to get by: control, compartmentalization, moving forward. But eventually, I began to wonder if the assumptions I made about trauma, like the ones I questioned at work, were incomplete.

Two years before I retired, I heard about ayahuasca on a podcast. It is a psychedelic preparation made from an Amazonian vine and a companion plant, used in ceremonial traditions for generations. What surprised me was not just what it was, but how it was discussed: with respect, even reverence.

This challenged a fundamental tenet of my law enforcement programming. As a product of the war on drugs, I believed that all illegal drugs were dangerous and destructive.

But after decades of watching cycles of addiction repeat themselves, and after losing my younger brother to heroin, I was forced to question whether this understanding was too simplistic.

So I did what I was trained to do. I researched it.

For over a year, I immersed myself in research on trauma and psychedelic therapy. I read clinical studies and heard veterans and others describe deep and often lasting healing and relief. At first, I was driven by intellectual curiosity and a commitment to follow the evidence, even if the conclusion directly contradicted what I had been taught. But beneath that curiosity was something more personal: the recognition that the tools I had relied on to manage my grief for decades were no longer working for me.

For years, I dealt with grief as many in our field do, mostly by repressing it and soldiering on. These skills were enough to keep me in the job. But in the retreat, they left me stuck, circling the same unresolved loss with no way out.

After careful consideration, I chose to attend an ayahuasca ceremony. At that time, I had never used illegal drugs. My substances were limited to alcohol and tobacco, both legal, socially acceptable and, in my case, convenient ways to deal with the grief bubbling under the skin.

What I experienced with Ayahuasca was not an escape from grief, but a direct engagement with it. The breakthrough wasn’t immediate, but with deliberate work and preparation, I was finally able to sit with the loss of Amel and the deaths of my father and brother without walking away. It was a different process than what I’ve relied on throughout my career, not control or oppression, but forgiveness, surrender and understanding.

This experience ultimately led me to write From the Badge to the Vine, a memoir about what it took to deal with years of trauma and the limitations of the tools I once relied on to manage it.

After a career spent investigating other people’s problems, I saw how rarely first responders are equipped or willing to examine their own injuries. The skills that define the profession—control, composure, endurance—can also make it harder to recognize when something deeper needs attention.

Trauma does not go away because it is repressed or managed. For some of us, that reality may not come into focus until after work is done and the radio is turned off. For others, the impact appears much earlier, in strained relationships, harmful behaviors, or a growing sense that something is not right but cannot be easily named.

What I have learned through this process is that ignoring these signs comes at a cost. Even assuming that the tools we were given at the beginning of our careers are the only ones available to us.

It is my hope that others in this profession will allow themselves to turn their investigative eyes inward in an effort to serve themselves. Ask the tough questions. Do your research. Follow the evidence where it leads. Not all things we were taught to fear are the same, and not all wounds are visible.

Special Agent in Charge Kemmi Sadler (Ret.) is the founder of Legalize the Divine, which advocates for safe and legal access to ancient healing traditions. A former St.Augustine, Florida Police Department officer, he is also a speaker for the Law Enforcement Action Partnership, and the author of From the Badge to the Vine: A Federal Agent’s Awakening Through Ayahuasca.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

ATACH releases comprehensive report on the future of hemp

Published

on

By

The American Trade Association for Cannabis and Hemp (ATACH) today released the 2026 Hemp Intoxicants Report, an analysis of the federal and state regulatory landscape for hemp-derived products in light of the most important federal hemp law change since the 2018 Farm Bill.

In November 2025, Congress enacted PL 119-37, formally redefining hemp to exclude intoxicating products, closing a loophole that allowed an unregulated synthetic THC market to emerge.

“Congress has closed the Farm Bill loophole,” said ATACH President Michael Bronstein. “The policy environment remains dynamic: a CMS hemp pilot program is underway, the marijuana rescheduling process is underway, and states are moving and enacting their own laws around hemp intoxication. In fact, regulations are being written in real time. With the new federal definition of hemp set to take effect on November 12, 2026, the Hemp Intoxicants Report provides reports on today’s market, toxins and how. Next up is industry, regulators and for consumers”.

What the report contains
What Congress Amended – PL 119-37 replaces the delta-9-only standard with an all-THC framework, imposes a limit of 0.4 mg per container on finished products, and excludes synthetic and chemically modified cannabinoids from the definition of hemp and hemp cannabinoids, effective November 12, 2026.

State Overview – A comprehensive review of how states have responded, including six regulatory archetypes, enforcement actions in 24 states, and more than 45 bills pending in the 2025 and 2026 legislative sessions.

CBD moment – For the first time, CBD has a clear federal legal basis – but there is still no path for consumer products through the FDA.

THC Beverages – An emerging category creating its own regulatory conversation, distinct from other hemp intoxicants, and three state models gaining traction.

Transition year – How banks, insurers and supply chains are preparing ahead of the November deadline.

The 2006 Hemp Intoxicants Report is now available here.

For more information:
American Cannabis and Hemp Trade Association
attach.org/

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media